-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Wang Guiqiang, director of the Department of Infectious Diseases of Peking University First Hospital, said in Beijing on the 11th that the small molecule new coronavirus treatment drugs developed in China are in full swing for clinical trials, and if the clinical results are effective, it is expected to be approved for marketing
as soon as possible.
as soon as possible.
On the same day, the China Public Diplomacy Association held a briefing to introduce China's
optimization and adjustment of epidemic prevention and control measures.
Recently, the oral small molecule drug Paxlovid produced by Pfizer has not been included in China's medical insurance has received widespread attention, Wang Guiqiang said at the meeting when talking about related issues, China's domestic small molecule drugs are undergoing clinical trials, and it is believed that with the advancement of research and development, more and more related drugs will be marketed to meet clinical needs
.
optimization and adjustment of epidemic prevention and control measures.
Recently, the oral small molecule drug Paxlovid produced by Pfizer has not been included in China's medical insurance has received widespread attention, Wang Guiqiang said at the meeting when talking about related issues, China's domestic small molecule drugs are undergoing clinical trials, and it is believed that with the advancement of research and development, more and more related drugs will be marketed to meet clinical needs
.
In the 10th edition of the new coronavirus infection diagnosis and treatment plan announced in China, antiviral treatment includes nematevir tablets/ritonavir tablets combination package (referred to as "Paxlovid"), azvudine tablets, monoclonal antibodies, intravenous COVID-19 human immunoglobulin, convalescent plasma of convalescent patients, etc
.
.
Wang Guiqiang said that antiviral therapy is an important part of comprehensive treatment, and small molecule drugs are convenient for oral use in community family outpatient clinics, which is the biggest advantage, and the current demand is indeed very large
.
He also pointed out that small molecule oral antivirals are generally best used within 5 days of infection, and the effect is not good
after 5 days.
In addition, priority use for people at high risk of severe disease, that is, the elderly, people with underlying diseases, and people who have not been vaccinated can reduce the risk of severe disease, and the use value of the general population after infection is not large
.
.
He also pointed out that small molecule oral antivirals are generally best used within 5 days of infection, and the effect is not good
after 5 days.
In addition, priority use for people at high risk of severe disease, that is, the elderly, people with underlying diseases, and people who have not been vaccinated can reduce the risk of severe disease, and the use value of the general population after infection is not large
.
